CA2238434A1 - Method for obtaining retroviral vector supernatant having high transduction efficiency - Google Patents

Method for obtaining retroviral vector supernatant having high transduction efficiency Download PDF

Info

Publication number
CA2238434A1
CA2238434A1 CA 2238434 CA2238434A CA2238434A1 CA 2238434 A1 CA2238434 A1 CA 2238434A1 CA 2238434 CA2238434 CA 2238434 CA 2238434 A CA2238434 A CA 2238434A CA 2238434 A1 CA2238434 A1 CA 2238434A1
Authority
CA
Canada
Prior art keywords
cells
vector
supernatant
propak
retroviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2238434
Other languages
English (en)
French (fr)
Inventor
Richard J. Rigg
Jonathan S. Dando
Sean P. Forestell
Ernst Bohnlein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Systemix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/572,959 external-priority patent/US5910434A/en
Application filed by Systemix Inc filed Critical Systemix Inc
Publication of CA2238434A1 publication Critical patent/CA2238434A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CA 2238434 1995-12-15 1996-12-13 Method for obtaining retroviral vector supernatant having high transduction efficiency Abandoned CA2238434A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57294395A 1995-12-15 1995-12-15
US08/572,943 1995-12-15
US08/572,959 US5910434A (en) 1995-12-15 1995-12-15 Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US08/572,959 1995-12-15

Publications (1)

Publication Number Publication Date
CA2238434A1 true CA2238434A1 (en) 1997-06-19

Family

ID=27075989

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2238434 Abandoned CA2238434A1 (en) 1995-12-15 1996-12-13 Method for obtaining retroviral vector supernatant having high transduction efficiency

Country Status (5)

Country Link
EP (1) EP0871753A2 (ja)
JP (1) JP2000501614A (ja)
AU (1) AU1333797A (ja)
CA (1) CA2238434A1 (ja)
WO (1) WO1997021824A2 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6790614B1 (en) 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
EP1807510A4 (en) 2004-09-24 2008-01-23 Angioblast Systems Inc MEMP (MULTIPOTENTIAL EXPANDED MESENCHYMAL PRECURSOR CELL PROGENY) AND USES THEREOF
KR20070085288A (ko) 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
ES2654428T3 (es) 2005-04-12 2018-02-13 Mesoblast, Inc. Aislamiento de células multipotenciales adultas por fosfatasa alcalina no específica de tejido
US8609411B2 (en) 2007-05-04 2013-12-17 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
KR20150021587A (ko) 2007-08-06 2015-03-02 메소블라스트, 아이엔씨. 생체 내에서 결합 조직을 생성, 복구 및/또는 유지하는 방법
ES2644089T3 (es) * 2007-12-27 2017-11-27 Baxalta GmbH Procedimientos de cultivo celular
KR101713343B1 (ko) 2008-08-18 2017-03-22 메소블라스트, 아이엔씨. 단일 클론 항체 ｓｔｒｏ-4
EP2879684B1 (en) 2012-08-01 2019-01-30 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
JP6901823B2 (ja) 2012-08-01 2021-07-14 ユナイテッド セラピューティクス コーポレイション 間葉系幹細胞による肺動脈性高血圧症の処置
CA2897805C (en) 2013-01-09 2023-03-21 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
JP6599848B2 (ja) 2013-05-10 2019-10-30 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルタギング可能なタンパク質を有する赤血球のｉｎｖｉｔｒｏ生成
FI3851537T3 (fi) * 2014-04-25 2024-03-21 Genethon Hyperbilirubinemian hoito
MY186199A (en) 2014-11-05 2021-06-30 Juno Therapeutics Inc Methods for transduction and cell processing
KR102606101B1 (ko) 2016-10-24 2023-11-27 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐에 의한 msc 면역조절 특성의 향상
EP4039786A1 (en) 2017-10-16 2022-08-10 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
WO2024075819A1 (ja) * 2022-10-07 2024-04-11 Ａｇｃ株式会社 細胞を用いたウイルスベクターの生産方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1315719C (en) * 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
JP3866760B2 (ja) * 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
ATE287732T1 (de) * 1994-08-17 2005-02-15 Genetic Therapy Inc Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden

Also Published As

Publication number Publication date
AU1333797A (en) 1997-07-03
EP0871753A2 (en) 1998-10-21
WO1997021824A3 (en) 1997-09-04
JP2000501614A (ja) 2000-02-15
WO1997021824A2 (en) 1997-06-19

Similar Documents

Publication Publication Date Title
EP0871754B1 (en) Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
WO1997021825A9 (en) Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
CA2238434A1 (en) Method for obtaining retroviral vector supernatant having high transduction efficiency
RIGG et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety
Weijtens et al. A retroviral vector system ‘STITCH’in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes
EP0598029B1 (en) Retroviral vectors containing internal ribosome entry sites
Persons et al. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene
JP5760023B2 (ja) 安全性の改善された発現ベクター
Forestell et al. Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transfer
US5710037A (en) Retroviral vector particles
Kim et al. Retroviral vectors
WO1997017457A2 (en) Stable packaging cell line producing pseudotyped retroviruses
WO1998013511A1 (en) Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
WO1998013511A9 (en) Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
van Heuvel et al. Establishment of a novel stable human suspension packaging cell line producing ecotropic retroviral MLV (PVC-211) vectors efficiently transducing murine hematopoietic stem and progenitor cells
CA2216868A1 (en) High efficiency ex vivo transduction of hematopoietic stem cells by recombinant retroviral preparations
Howe et al. Vector systems for prenatal gene therapy: principles of retrovirus vector design and production
US5766945A (en) 10A1 Retroviral packaging cells and uses thereof
KR100359542B1 (ko) 레트로바이러스 벡터를 위한 부유성 패키징 세포주
US20020164800A1 (en) Retroviral vector
Anson Retroviral-mediated gene transduction
Takeuchi et al. Retrovirus vectors
EP1081227A1 (en) Methods and means for retroviral gene delivery
Dando The Biology of the Stem Cell and Its Environment in the Role of Effective Gene Therapy
Garoff et al. Alphavirus-Retrovirus Vectors Henrik Garoff and Kejun Li Karolinska Institutet, Dept. of Biosciences at Novum 141 57 HUDDINGE, Sweden

Legal Events

Date Code Title Description
FZDE Dead